An Open-Label, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B.
Phase of Trial: Phase IV
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Telbivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Novartis
- 10 May 2012 Actual end date (September 2010) added as reported by ClinicalTrials.gov.
- 03 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 May 2011 Planned End Date changed from 1 Aug 2010 to 1 May 2011 as reported by ClinicalTrials.gov.